PIPELINE
LEAD
PROGRAMS
Status: Phase 1
Novel, first-in-class compound for liver cancer, which is the fastest growing cancer in the US and EU, and has a high prevalence in Asia.
AU-018 for Heart-Safe Chemotherapy
Status: IND enabling
Heart-safe chemotherapy for the $1B anthracycline chemotherapy market, to help improve tolerability and raise the standard of cancer care.
Our growing pipeline of novel cancer drug candidates
PRECLINICAL
DISCOVERY
DISEASE AREA*
CLINICAL
*Among 70+ diseases analyzed, in discovery or early preclinical stage
100+
Classic
Diseases
Our focus is on advancing novel therapies that raise the standard of care for cancer patients, by generating more personalized treatments for cancers, cancer-related diseases, and subtypes of cancer we have yet to define.